Median progression-free survival was significantly higher for the doxorubicin and ifosfamide group ( 74 months [ 95 % CI 66-83 ] ) than for the doxorubicin group ( 46 months [ 29-56 ] ; HR 074 [ 95 % CI 060-090 ] , stratified log-rank test p = 0003 ) .